In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313

Immunity. 2025 Feb 11;58(2):499-512.e7. doi: 10.1016/j.immuni.2025.01.009. Epub 2025 Feb 4.

Abstract

Genetic engineering of T cells in mouse models is essential for investigating immune mechanisms. We aimed to develop an approach to manipulate T cells in vivo using an evolved adeno-associated virus (AAV) capsid named Ark313. Delivery of a transient transgene expression cassette was feasible using Ark313, and this serotype outperformed natural serotypes. A single intravenous injection of a Cre recombinase-expressing Ark313 in the Ai9 fluorescent reporter mouse model achieved permanent genetic modifications of T cells. Ark313 facilitated in vivo gene editing in both tissue-resident and splenic T cells and validation of immunotherapy targets in solid tumor models. Ark313 delivered large DNA donor templates to T cells in vivo and integrated transgenes in primary CD4+ and CD8+ T cells, including naive T cells. Ark313-mediated transgene delivery presents an efficient approach to target mouse T cells in vivo and a resource for the interrogation of T cell biology and for immunotherapy applications.

Keywords: AAV; Ark313; T cell engineering; gene targeting; immune therapy; in vivo delivery; in vivo gene editing; knockin; mouse T cells.

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes* / immunology
  • CD8-Positive T-Lymphocytes* / immunology
  • Capsid Proteins / genetics
  • Dependovirus* / genetics
  • Dependovirus* / immunology
  • Gene Editing / methods
  • Genetic Engineering / methods
  • Genetic Vectors / genetics
  • Humans
  • Integrases / genetics
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • T-Lymphocytes* / immunology
  • Transgenes / genetics

Substances

  • Integrases
  • Capsid Proteins